Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Wyeth Pharmaceuticals
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Non-Malignant Pain
The primary objectives are: 1) To establish the dose-response relationship of MOA-728 by observing spontaneous bowel movements, and to establish appropriate doses to take into confirmatory phase 3 stu...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company
Update Il y a 4 ans
An Open-label, Single-Arm, Phase 2 Study of Inotuzumab Ozogamicin Plus Rituximab in Subjects With Relapsed/Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible for Autologous Stem Cell Transplantation
To evaluate efficacy and safety of inotuzumab ozogamicin in combination with rituximab when used as induction therapy prior to consolidation with HD chemo and aSCT in subjects with relapsed/refractory...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 75 MG AND 150 MG DOSES OF ERB-041 ON THE REDUCTION OF SYMPTOMS ASSOCIATED WITH ENDOMETRIOSIS DURING TREATMENT AND POST TREATMENT IN REPRODUCTIVE-AGED WOMEN
-To evaluate the superiority of ERB-041 relative to placebo on the relief of endometriosis-related symptoms (dysmenorrhea, pelvic pain, and deep dyspareunia) in reproductive-aged women using the Biber...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals France
Update Il y a 4 ans
'A multicenter double-blind, placebo-controlled randomized pilot study evaluating efficacy and safety of ETN in patients with moderate to severe plaque psoriasis after cessation of ciclosporin therapy'
To demonstrate the sustained efficacy and safety of etancercept as a replacement therapy for ciclosporin in patients with moderate to severe plaque psoriasis who have achieved an adequate response wit...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A 4-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE PRELIMINARY EFFICACY, SAFETY, AND PHARMACOKINETICS OF PPM-204 ADMINISTERED ORALLY TO TREATMENT-NAÏVE SUBJECTS WITH TYPE II DIABETES MELLITUS
To determine the glucose lowering effects of PPM-204 in subjects with type 2 diabetes mellitus.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development
Update Il y a 4 ans
A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy
To compare the efficacy and the safety of 3 dose levels of oral ERB-041 administered daily for 12 weeks versus palcebo in subjects with active RA who had a suboptimal response to therapy with stable d...
Country
None
organs
None
Specialty
None
Closed trial
More information
Wyeth Pharmaceuticals (The Netherlands) - unrestricted grant
Update Il y a 4 ans
Short-term cognitive behavioural therapy and short-term psychoanalytical supportive psychotherapy as treatment for depression: a randomised clinical trial
Not provided at time of registration
Country
Netherlands
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation Estudio multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, de MOA-728 subcutánea para el tratamiento del estreñimiento inducido por opiáceos
Primary: To evaluate the safety, efficacy, and tolerability of subcutaneous MOA-728 versus placebo in subjects with nonmalignant pain who have opioid-induced constipation.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals Inc. (a Pfizer Company)
Update Il y a 4 ans
Trial of vaccine in HIV patients from 6 years old to older
To evaluate the immune responses 1 month after 3 doses of 13vPnC compared to 1 month after 2 doses of 13vPnC as measured by fold rises of serotype-specific immunoglobulin G (IgG) geometric mean antibo...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals Inc., acting through its division Wyeth research, a Pfizer company
Update Il y a 4 ans
3003: PH 3, HIGH RISK RECIPIENTS OF ALLOGENEIC HSCT >/= 2 YR
To evaluate the immune responses 1 month after 3 doses of 13vPnC as measured by fold rises of serotype specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) in subjects ≥2 years of age.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next